Table 8 12-year return-on-investment (ROI) for early-treatment (per patient screened) for ranibizumab therapy for neovascular AMD
From: A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration
12-year costs (US 2012 real dollars) associated with early-treatment vs. late-treatment ranibizumab therapy | Genetic screening/monitoring costs expended (%) per patient screened | Negative societal costs returned for genetic costs expended (%Â =Â percent of total costs returned) | Net final cost | 12-year financial return-on-investment (ROI) | Diminution in usual cost due to costs returned from genetic testing |
|---|---|---|---|---|---|
Overall costs | $2205 (100 %) | (−$7500) (100 %) | (−$5295) | 240 % | 340 % |
Medicare (Medicare pays 80 % of Part B costs) | $1559 (70.7 %) | (−$548) (7.3 %) | $1011 | −65 %a | 35 % |
Medicaid | $84 (3.8 %) | (−$53) (0.7 %) | $31 | −37 %a | 63 % |
Commercial insurance (Medi-gap policies covering 20 % of approved Medicare cost) | $348 (15.8 %) | (−$83) (1.1 %) | $266 | −78 %a | 22 % |
Commercial insurance (under age 65 years) | $174 (7.9 %) | (−$53) (0.7 %) | $122 | −76 % | 24 % |
Patients (NB. Healthcare insurance costs are not included) | $40 (1.8 %) | (−$6765) (90.2 %) | (−$6725) | 16,945 % | 17,045 % |